Likewise, Marabelle et al. recently demonstrated that combined anti-OX40/anti-CTLA-4 (with adjuvant CpG) was capable of inducing regression of local and distant tumors using several aggressive tumor models when administered intra-tumorally. The gene discussed is TNFRSF4; the disease is neoplasm.